H1N1 Vaccine Trials: NIH Will Mix And Match Antigens, Adjuvants
Executive Summary
The National Institutes of Health is developing a plan B as H1N1 vaccine manufacturers race to produce enough product by the start of flu season. The agency is going to mix and match antigen and adjuvant from different sponsors to try to find the best immunogenicity
You may also be interested in...
H1N1 Vaccine Update: Big Sales To Come In Fourth Quarter, Mfrs. Say
The pandemic influenza situation is leaving the biopharmaceutical industry in a healthy state - with early reports of vaccine sales having notable impact on manufacturers' bottom lines, revitalization for waning antiviral products and accelerated pathways for novel products
H1N1 Vaccine Update: Big Sales To Come In Fourth Quarter, Mfrs. Say
The pandemic influenza situation is leaving the biopharmaceutical industry in a healthy state - with early reports of vaccine sales having notable impact on manufacturers' bottom lines, revitalization for waning antiviral products and accelerated pathways for novel products
H1N1 Vaccine Makers Get New Virus Strains In Hopes Of Increasing Yield
Adequate supply of the vaccine is key to FDA's determination of whether to approve adjuvanted H1N1 vaccines.